Control Bionics

Control Bionics Supply Chain

Supply Chain of Control Bionics (CBL.AX) as of Nov 3, 2026.

Supply Chain

-

Last updated:

Supply chains in stock corporations are essential components of business infrastructure and play a crucial role in value creation and competitiveness. These supply chains encompass all steps from raw material procurement and production to the delivery of finished products to the end customer.

Control Bionics Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
4 companies
#NameTrend
1
Intel
Supplier·Semiconductors & Semiconductor Equipment·US
0.48
0.58
0.12
0.44
0.71
—
2
Alphabet A
Supplier·Interactive Media & Services·US
0.17
0.54
0.30
0.60
0.04
—
3
Apple
Supplier·Technology Hardware, Storage & Peripherals·US
-0.06
0.46
0.23
0.08
-0.69
—
4
Microsoft
Supplier·Software·US
-0.41
-0.08
0.10
0.65
-0.24
—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Control Bionics Stock analysis

What does Control Bionics do? Control Bionics Ltd. generates revenue through the sale of its NeuroNode Trilogy, NeuroNode Duo, Eye-gaze Duo, and DROVE systems, which are designed for patients with communication impairments due to conditions like motor neuron disease and amyotrophic lateral sclerosis. The company's NeuroNode technology detects brain signals to skeletal muscles, converting them into EMG output that enables wireless communication via personal computers for speech, email, and texting. Its products integrate with eye-gaze technology, allowing cursor movement on screens as a mouse alternative, with the NeuroNode functioning as the mouse button. These systems are primarily purchased by healthcare providers and rehabilitation centers serving patients with severe motor disabilities. The company's core products include NeuroNode Trilogy, NeuroNode Duo, Eye-gaze Duo, and DROVE, each tailored to specific communication and mobility needs. NeuroNode Trilogy and NeuroNode Duo focus on EMG-based communication, while Eye-gaze Duo combines eye-tracking with the NeuroNode for cursor control. DROVE is another core system that supports additional functionalities. Healthcare institutions and rehabilitation facilities are the primary buyers, as they deploy these technologies to assist patients with conditions such as motor neuron disease and amyotrophic lateral sclerosis who require augmentative and alternative communication solutions. Control Bionics Ltd. targets medical and rehabilitation sectors, specifically those dealing with patients suffering from motor neuron disease, amyotrophic lateral sclerosis, and similar conditions. The NeuroNode technology is sold as a complete system, including wireless wearable devices and integration with eye-gaze systems, to enable seamless communication through computer-controlled functions. Revenue is derived from direct sales of these systems to healthcare providers who serve individuals with compromised verbal and text-based communication abilities. Control Bionics is one of the most popular companies on Eulerpool.

All Key Metrics — Control Bionics